Key Points
-
The recent failure of novel anti-atherosclerotic therapies in Phase III clinical trials has emphasized the pressing need for robust imaging markers that can reliably assist in the development of drugs for the treatment of atherosclerosis.
-
Conventional methods of imaging atherosclerosis are able to provide quantitative and morphological data, and to date, have principally been used to assess the efficacy of cholesterol-lowering agents.
-
In this article we compare the main imaging modalities used to image atherosclerosis in the clinical trial setting so far, namely quantitative coronary angiography (QCA), carotid intima-media thickness (CIMT), magnetic resonance imaging (MRI), computed tomography (CT) and intravascular ultrasound (IVUS). The ability of these imaging modalities to predict clinical outcomes for a given sample size, and the regulatory considerations pertaining to their use, are also discussed.
-
However, these methods are likely to be inadequate to assess an emerging generation of therapies that modify plaque biology directly. For example, squalene synthase inhibitors, p38 mitogen-activated protein kinase (MAPK) inhibitors, and chemokine (C-C motif) receptor 2 (CCR2) antagonists.
-
We outline how emerging molecular and cellular imaging techniques offer the possibility to quantify changes in biological function at the level of the plaque, even without gross structural change. In this regard, two imaging modalities are discussed in detail: MRI and positron-emission tomography (PET).
-
Currently, no single ideal imaging modality exists. In the future, the careful application of imaging biomarkers will be necessary to ensure that new anti-atherosclerosis therapies are evaluated in the most efficient manner possible.
Abstract
There is a pressing need for robust imaging markers to assist in the development of drugs for the treatment of atherosclerosis. Conventional imaging methods provide quantitative and morphological data but may be inadequate for assessing a new generation of therapies that modify plaque biology directly. Here, we compare the main imaging modalities used to image atherosclerosis in the clinical-trial setting, and assess their ability to predict clinical outcomes for a given sample size. We consider how emerging molecular and cellular imaging techniques could offer the possibility to quantify changes in biological function at the level of the plaque, even without gross structural change.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
[No authors listed]. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 2, 349–360 (1988).
[No authors listed]. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383–1389 (1994).
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7–22 (2002).
[No authors listed]. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 355, 253–259 (2000).
Dormandy, J. A. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366, 1279–1289 (2005).
Tall, A. R. CETP inhibitors to increase HDL cholesterol levels. N. Engl. J. Med. 356, 1364–1366 (2007).
Tall, A. R., Yvan-Charvet, L. & Wang, N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler. Thromb. Vasc. Biol. 27, 257–260 (2007).
Libby, P. Inflammation in atherosclerosis. Nature 420, 868–874 (2002).
Brown, B. G., Bolson, E., Frimer, M. & Dodge, H. T. Quantitative coronary arteriography: estimation of dimensions, hemodynamic resistance, and atheroma mass of coronary artery lesions using the arteriogram and digital computation. Circulation 55, 329–337 (1977).
Blankenhorn, D. H. et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257, 3233–3240 (1987).
Brown, B. G. et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345, 1583–1592 (2001).
Glagov, S., Weisenberg, E., Zarins, C. K., Stankunavicius, R. & Kolettis, G. J. Compensatory enlargement of human atherosclerotic coronary arteries. N. Engl. J. Med. 316, 1371–1375 (1987).
Topol, E. J. & Nissen, S. E. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation 92, 2333–2342 (1995). An excellent review article highlighting the shortcomings of coronary angiography for plaque assessment.
Schoenhagen, P. et al. Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial. Circulation 113, 2826–2834 (2006).
Simons, P. C., Algra, A., Bots, M. L., Grobbee, D. E. & van der Graaf, Y. Common carotid intima-media thickness and arterial stiffness: indicators of cardiovascular risk in high-risk patients. The SMART Study (Second Manifestations of ARTerial disease). Circulation 100, 951–957 (1999).
Bots, M. L., Hoes, A. W., Koudstaal, P. J., Hofman, A. & Grobbee, D. E. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 96, 1432–1437 (1997).
Yamasaki, Y. et al. Carotid intima-media thickness in Japanese type 2 diabetic subjects: predictors of progression and relationship with incident coronary heart disease. Diabetes Care 23, 1310–1315 (2000).
Hodis, H. N. et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann. Intern. Med. 128, 262–269 (1998).
Salonen, J. T., Seppanen, K., Rauramaa, R. & Salonen, R. Risk factors for carotid atherosclerosis: the Kuopio Ischaemic Heart Disease Risk Factor Study. Ann. Med. 21, 227–229 (1989).
Chambless, L. E. et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. Am. J. Epidemiol. 146, 483–94 (1997).
Blankenhorn, D. H. et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation 88, 20–28 (1993).
MacMahon, S. et al. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation 97, 1784–1790 (1998).
de Groot, E. et al. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study. Am. J. Cardiol. 76, 40C–46C (1995).
Crouse, J. R., 3rd et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am. J. Cardiol. 75, 455–459 (1995).
Crouse, J. R., 3rd et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 297, 1344–1353 (2007).
Duivenvoorden, R., Nederveen, A. J., de Groot, E. & Kastelein, J. J. Atherosclerosis imaging as benchmark in the development of novel cardiovascular drugs. Curr. Opin. Lipidol. 18, 613–621 (2007).
Kastelein, J. J. et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358, 1431–1443 (2008).
Bots, M. L., Evans, G. W., Riley, W. A. & Grobbee, D. E. Carotid intima-media thickness measurements in intervention studies: design options, progression rates, and sample size considerations: a point of view. Stroke 34, 2985–2994 (2003). A comprehensive review of the use of carotid ultrasound imaging in trials.
Taylor, A. J. et al. Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project. J. Am. Coll. Cardiol. 46, 807–814 (2005).
Achenbach, S. et al. Detection of calcified and noncalcified coronary atherosclerotic plaque by contrast-enhanced, submillimeter multidetector spiral computed tomography: a segment-based comparison with intravascular ultrasound. Circulation 109, 14–17 (2004).
Leber, A. W. et al. Accuracy of multidetector spiral computed tomography in identifying and differentiating the composition of coronary atherosclerotic plaques: a comparative study with intracoronary ultrasound. J. Am. Coll. Cardiol. 43, 1241–1247 (2004).
Leber, A. W. et al. Accuracy of 64-slice computed tomography to classify and quantify plaque volumes in the proximal coronary system: a comparative study using intravascular ultrasound. J. Am. Coll. Cardiol. 47, 672–677 (2006).
Hyafil, F. et al. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nature Med. 13, 636–641 (2007).
O'Malley, P. G., Taylor, A. J., Jackson, J. L., Doherty, T. M. & Detrano, R. C. Prognostic value of coronary electron-beam computed tomography for coronary heart disease events in asymptomatic populations. Am. J. Cardiol. 85, 945–948 (2000).
Detrano, R. et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N. Engl. J. Med. 358, 1336–1345 (2008). The first study to investigate the relationship between CT coronary artery calcium score and the incidence of coronary events in a multi-ethnic population.
Ardehali, R., Nasir, K., Kolandaivelu, A., Budoff, M. J. & Blumenthal, R. S. Screening patients for subclinical atherosclerosis with non-contrast cardiac CT. Atherosclerosis 192, 235–242 (2007).
Raggi, P. et al. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). Circulation 112, 563–571 (2005).
Terry, J. G. et al. Effect of simvastatin (80 mg) on coronary and abdominal aortic arterial calcium (from the coronary artery calcification treatment with zocor [CATZ] study). Am. J. Cardiol. 99, 1714–1717 (2007).
Nicholls, S. J. et al. Coronary artery calcification and changes in atheroma burden in response to established medical therapies. J. Am. Coll. Cardiol. 49, 263–270 (2007).
Redberg, R. F. et al. 34th Bethesda Conference: Task force #3 — What is the spectrum of current and emerging techniques for the noninvasive measurement of atherosclerosis? J. Am. Coll. Cardiol. 41, 1886–1898 (2003).
Einstein, A. J., Henzlova, M. J. & Rajagopalan, S. Estimating risk of cancer associated with radiation exposure from 64-slice computed tomography coronary angiography. JAMA 298, 317–323 (2007).
Einstein, A. J., Moser, K. W., Thompson, R. C., Cerqueira, M. D. & Henzlova, M. J. Radiation dose to patients from cardiac diagnostic imaging. Circulation 116, 1290–1305 (2007). A detailed review of the radiation exposure risks associated with all forms of cardiac imaging.
Husmann, L. et al. Feasibility of low-dose coronary CT angiography: first experience with prospective ECG-gating. Eur. Heart J. 29, 191–197 (2008).
Nissen, S. E. Application of intravascular ultrasound to characterize coronary artery disease and assess the progression or regression of atherosclerosis. Am. J. Cardiol. 89, 24B–31B (2002).
Nissen, S. E. & Yock, P. Intravascular ultrasound: novel pathophysiological insights and current clinical applications. Circulation 103, 604–616 (2001).
Prati, F. et al. Correlation between high frequency intravascular ultrasound and histomorphology in human coronary arteries. Heart 85, 567–570 (2001).
Kawasaki, M. et al. In vivo quantitative tissue characterization of human coronary arterial plaques by use of integrated backscatter intravascular ultrasound and comparison with angioscopic findings. Circulation 105, 2487–2492 (2002).
Nissen, S. E. et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291, 1071–1080 (2004). A large IVUS trial demonstrating that high-dose statin therapy can impede progression of coronary artery disease.
Nissen, S. E. et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295, 1556–1565 (2006).
Nissen, S. E. et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290, 2292–2300 (2003).
Nissen, S. E. et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 356, 1304–1316 (2007).
Nissen, S. E. et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N. Engl. J. Med. 354, 1253–1263 (2006).
von Birgelen, C. et al. Relationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries. Circulation 110, 1579–1585 (2004).
Brown, B. G. A direct comparison of intravascular ultrasound and quantitative coronary arteriography: implications for measures of atherosclerosis as clinical surrogates. Circulation 115, 1824–1826 (2007).
Corti, R. et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 106, 2884–2887 (2002).
Corti, R. et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J. Am. Coll. Cardiol. 46, 106–112 (2005).
Ayaori, M. et al. Effect of bezafibrate therapy on atherosclerotic aortic plaques detected by MRI in dyslipidemic patients with hypertriglyceridemia. Atherosclerosis 196, 425–433 (2006).
Fayad, Z. A. & Fuster, V. Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. Circ. Res. 89, 305–316 (2001).
Choudhury, R. P., Fuster, V., Badimon, J. J., Fisher, E. A. & Fayad, Z. A. MRI and characterization of atherosclerotic plaque: emerging applications and molecular imaging. Arterioscler. Thromb. Vasc. Biol. 22, 1065–1074 (2002).
Saam, T. et al. Quantitative evaluation of carotid plaque composition by in vivo MRI. Arterioscler. Thromb. Vasc. Biol. 25, 234–239 (2005).
Kampschulte, A. et al. Differentiation of intraplaque versus juxtaluminal hemorrhage/thrombus in advanced human carotid atherosclerotic lesions by in vivo magnetic resonance imaging. Circulation 110, 3239–3244 (2004).
Cai, J. et al. In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque: comparison of high-resolution, contrast-enhanced magnetic resonance imaging and histology. Circulation 112, 3437–3444 (2005).
Marckmann, P. et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J. Am. Soc. Nephrol. 17, 2359–2362 (2006).
Zhao, X. Q. et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler. Thromb. Vasc. Biol. 21, 1623–1629 (2001).
Underhill, H. R. et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am. Heart J. 155, 584.e1–584.e8 (2008).
Kastelein, J. J. et al. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Curr. Med. Res. Opin. 23, 885–894 (2007).
Navab, M. et al. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 109, 3215–3220 (2004).
Tardif, J. C. et al. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 110, 3372–3377 (2004).
Zhao, X. Q. et al. Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by magnetic resonance imaging: study design of Carotid Plaque Composition Study. Am. Heart J. 154, 239–246 (2007).
Choudhury, R. P., Fuster, V. & Fayad, Z. A. Molecular, cellular and functional imaging of atherothrombosis. Nature Rev. Drug Discov. 3, 913–925 (2004).
Jaffer, F. A., Libby, P. & Weissleder, R. Molecular imaging of cardiovascular disease. Circulation 116, 1052–1061 (2007).
Jaffer, F. A. et al. Age and sex distribution of subclinical aortic atherosclerosis: a magnetic resonance imaging examination of the Framingham Heart Study. Arterioscler. Thromb. Vasc. Biol. 22, 849–854 (2002).
Yabushita, H. et al. Characterization of human atherosclerosis by optical coherence tomography. Circulation 106, 1640–1645 (2002). The first study to assess the accuracy of OCT for diagnosing plaque type.
Tearney, G. J. et al. Quantification of macrophage content in atherosclerotic plaques by optical coherence tomography. Circulation 107, 113–119 (2003).
Rogowska, J., Patel, N. A., Fujimoto, J. G. & Brezinski, M. E. Optical coherence tomographic elastography technique for measuring deformation and strain of atherosclerotic tissues. Heart 90, 556–562 (2004).
Yang, V. X. et al. Interstitial Doppler optical coherence tomography. Opt. Lett. 30, 1791–1793 (2005).
Giattina, S. D. et al. Assessment of coronary plaque collagen with polarization sensitive optical coherence tomography (PS-OCT). Int. J. Cardiol. 107, 400–409 (2006).
Spence, J. D. Technology Insight: ultrasound measurement of carotid plaque — patient management, genetic research, and therapy evaluation. Nature Clin. Pract. Neurol. 2, 611–619 (2006).
Barnett, P. A., Spence, J. D., Manuck, S. B. & Jennings, J. R. Psychological stress and the progression of carotid artery disease. J. Hypertens. 15, 49–55 (1997).
Spence, J. D. Ultrasound measurement of atherosclerosis. Stroke 35, e87–e88; author reply e87–e8 (2004).
Ainsworth, C. D. et al. 3D ultrasound measurement of change in carotid plaque volume: a tool for rapid evaluation of new therapies. Stroke 36, 1904–1909 (2005).
Takayama, T. et al. Rationale and design for a study using intravascular ultrasound to evaluate effects of rosuvastatin on coronary artery atheroma in Japanese subjects: COSMOS study (Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects). Circ. J. 71, 271–275 (2007).
Saam, T. et al. Sample size calculation for clinical trials using magnetic resonance imaging for the quantitative assessment of carotid atherosclerosis. J. Cardiovasc. Magn. Reson. 7, 799–808 (2005).
Corti, R. et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 104, 249–252 (2001). The first prospective study demonstrating the ability of non-invasive MRI to show changes in atherosclerotic plaque in response to statin therapy.
Lee, J. M. et al. Early changes in arterial structure and function following statin initiation: quantification by magnetic resonance imaging. Atherosclerosis 197, 951–958 (2008).
Revkin, J. H., Shear, C. L., Pouleur, H. G., Ryder, S. W. & Orloff, D. G. Biomarkers in the prevention and treatment of atherosclerosis: need, validation, and future. Pharmacol. Rev. 59, 40–53 (2007).
Moreno, P. R. et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 94, 3090–3097 (1996).
Choudhury, R. P., Lee, J. M. & Greaves, D. R. Mechanisms of disease: macrophage-derived foam cells emerging as therapeutic targets in atherosclerosis. Nature Clin. Pract. Cardiovasc. Med. 2, 309–315 (2005).
Cullen, J. P. et al. Resveratrol inhibits expression and binding activity of the monocyte chemotactic protein-1 receptor, CCR2, on THP-1 monocytes. Atherosclerosis 195, e125–e133 (2007).
Morris, J. B. et al. p38 MAPK inhibition reduces aortic ultrasmall superparamagnetic iron oxide uptake in a mouse model of atherosclerosis: MRI assessment. Arterioscler. Thromb. Vasc. Biol. 28, 265–271 (2008).
Tardif, J. C. et al. Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial. Atherosclerosis 197, 480–486 (2008).
Doggrell, S. A. & Wanstall, J. C. Vascular chymase: pathophysiological role and therapeutic potential of inhibition. Cardiovasc. Res. 61, 653–662 (2004).
Rudd, J. H. et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 105, 2708–2711 (2002). The first description of the use of FDG–PET to demonstrate atherosclerotic plaque inflammation.
Tawakol, A. et al. In vivo18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J. Am. Coll. Cardiol. 48, 1818–1824 (2006).
Tahara, N. et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J. Am. Coll. Cardiol. 48, 1825–1831 (2006).
Rudd, J. H. et al. 18Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J. Am. Coll. Cardiol. 50, 892–896 (2007).
Madjid, M., Zarrabi, A., Litovsky, S., Willerson, J. T. & Casscells, W. Finding vulnerable atherosclerotic plaques: is it worth the effort? Arterioscler. Thromb. Vasc. Biol. 24, 1775–1782 (2004).
Casscells, W., Naghavi, M. & Willerson, J. T. Vulnerable atherosclerotic plaque: a multifocal disease. Circulation 107, 2072–2075 (2003).
Breyholz, H. J. et al. C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging. J. Med. Chem. 48, 3400–3409 (2005).
Cohen, J. C., Boerwinkle, E., Mosley, T. H., Jr & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264–1272 (2006).
Cauchon, N. et al. PET imaging of apoptosis with 64Cu-labeled streptavidin following pretargeting of phosphatidylserine with biotinylated annexin-V. Eur. J. Nucl. Med. Mol. Imaging 34, 247–258 (2007).
Nutt, R., Vento, L. J. & Ridinger, M. H. In vivo molecular imaging biomarkers: clinical pharmacology's new “PET”? Clin. Pharmacol. Ther. 81, 792–795 (2007).
Ruehm, S. G., Corot, C., Vogt, P., Kolb, S. & Debatin, J. F. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation 103, 415–422 (2001).
Kooi, M. E. et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 107, 2453–2458 (2003).
Schmitz, S. A. et al. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles. J. Magn. Reson. Imaging 14, 355–361 (2001).
Litovsky, S. et al. Superparamagnetic iron oxide-based method for quantifying recruitment of monocytes to mouse atherosclerotic lesions in vivo: enhancement by tissue necrosis factor-α, interleukin-1β, and interferon-γ. Circulation 107, 1545–1549 (2003).
Trivedi, R. A. et al. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler. Thromb. Vasc. Biol. 26, 1601–1606 (2006).
Amirbekian, V. et al. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc. Natl Acad. Sci. USA 104, 961–966 (2007).
Frias, J. C., Williams, K. J., Fisher, E. A. & Fayad, Z. A. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J. Am. Chem. Soc. 126, 16316–16317 (2004).
Winter, P. M. et al. Endothelial αvβ3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26, 2103–2109 (2006).
McAteer, M. A. et al. Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler. Thromb. Vasc. Biol. 28, 77–183 (2007).
Davies, M. J. et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J. Pathol. 171, 223–229 (1993).
McAteer, M. A. et al. In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide. Nature Med. 13, 1253–1258 (2007).
Kaufmann, B. A. et al. Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation 116, 276–284 (2007).
MacNeill, B. D. et al. Focal and multi-focal plaque macrophage distributions in patients with acute and stable presentations of coronary artery disease. J. Am. Coll. Cardiol. 44, 972–979 (2004).
Lee, J. M. & Choudhury, R. P. in Metabolic Syndrome and Cardiovascular Disease (eds Krentz, A.J. & Wong, N. D.) 79–108 (Taylor and Francis, New York, NY, 2006).
Jaffer, F. A. et al. Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation 115, 2292–2298 (2007).
Schmermund, A. et al. Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study. Risk Factors, Evaluation of Coronary Calcium and Lifestyle. Am. Heart J. 144, 212–218 (2002).
Joseph, S. B. et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl Acad. Sci. USA 99, 7604–7609 (2002).
Walcher, D. et al. LXR activation reduces proinflammatory cytokine expression in human CD4-positive lymphocytes. Arterioscler. Thromb. Vasc. Biol. 26, 1022–1028 (2006).
Li, A. C. et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ. J. Clin. Invest. 114, 1564–1576 (2004).
Li, X. et al. Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 110, 1701–1705 (2004).
Piper, E., Price, G. & Chen, Y. TAK-475, a squalene synthase inhibitor, improves lipid profile in hyperlipidemic subjects. Circulation 114, II_288 (2006).
Gaofu, Q. et al. Vaccinating rabbits with a cholesteryl ester transfer protein (CETP) B-Cell epitope carried by heat shock protein-65 (HSP65) for inducing anti-CETP antibodies and reducing aortic lesions in vivo. J. Cardiovasc. Pharmacol. 45, 591–598 (2005).
Okamoto, H. et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406, 203–207 (2000).
Miller, L. W. et al. Inhibition of transplant vasculopathy in a rat aortic allograft model after infusion of anti-inflammatory viral serpin. Circulation 101, 1598–1605 (2000).
Auge, N. et al. Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation of the sphingomyelin/ceramide pathway and smooth muscle cell proliferation. Circulation 110, 571–578 (2004).
Acknowledgements
Work in this laboratory is funded by the Wellcome Trust and the British Heart Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.P.C. has received research funding from GlaxoSmithKline and Merck (Darmstadt) for work involving atherosclerosis imaging with MRI. He has received travel awards/honoraria/speaker fees from or served as a consultant or on advisory boards to Merck, Sanofi Aventis, AstraZeneca, GlaxoSmithKline, Schering–Plough, Solvay Healthcare and Pfizer. R.P.C.'s work is supported by the Oxford Biomedical Research Centre, NIHR funding scheme.
Related links
Glossary
- B-mode (2-dimensional) ultrasound
-
A linear array of ultrasound transducers used to scan planes of the body to obtain a two-dimensional image.
- Acoustic shadow
-
An area through which ultrasound waves fail to propagate, most often due to obstruction by calcification, leading to loss of signal.
- Echogenicity
-
The ability to create a signal detectable by ultrasound.
- Integrated backscatter
-
A measure of the mean reflected ultrasonic energy from a particular region of tissue.
- Balloon angioplasty
-
A percutaneous procedure whereby a small balloon is inflated inside a tightly narrowed artery in order to relieve the obstruction.
- Stent
-
A rigid wire mesh inserted into a narrowed artery and expanded by balloon angioplasty to hold the artery open.
- Elastography
-
A method of assessing the integrity of a tissue by measuring its biomechanical properties, such as its stiffness or its response to strain.
- OCT Doppler
-
The use of optical coherence tomography (OCT) to estimate blood flow using the Doppler effect.
- Polarization-sensitive OCT
-
The use of optical coherence tomography (OCT) to measure tissue birefringence and estimate plaque collagen content.
- Carotid endarterectomy
-
A surgical procedure involving the removal of the core of plaques in the severely diseased or symptomatic artery in the neck.
Rights and permissions
About this article
Cite this article
Lindsay, A., Choudhury, R. Form to function: current and future roles for atherosclerosis imaging in drug development. Nat Rev Drug Discov 7, 517–529 (2008). https://doi.org/10.1038/nrd2588
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd2588
This article is cited by
-
Intra-coronary Imaging for the Evaluation of Plaque Modifications Induced by Drug Therapies for Secondary Prevention
Current Atherosclerosis Reports (2020)
-
Imaging the Coronary Artery Plaque: Approaches, Advances, and Challenges
Current Cardiovascular Imaging Reports (2017)
-
In-vivo quantitative T2 mapping of carotid arteries in atherosclerotic patients: segmentation and T2 measurement of plaque components
Journal of Cardiovascular Magnetic Resonance (2013)
-
Cardiac PET-CT and CT Angiography
Current Cardiovascular Imaging Reports (2013)
-
Nanocrystal Core Lipoprotein Biomimetics for Imaging of Lipoproteins and Associated Diseases
Current Cardiovascular Imaging Reports (2013)